[{"id":"1394e99e-c38f-44e4-ab4d-aee1d10301bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05507541","created_at":"2022-08-19T17:10:01.039Z","updated_at":"2025-02-25T12:28:56.881Z","phase":"Phase 2","brief_title":"TTI-622 in Combination with Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT05507541","lead_sponsor":"Mayo Clinic","biomarkers":" PD-L1 • ALK • BCL2 • BCL6 • IRF4","pipe":" | ","alterations":" ALK positive","tags":["PD-L1 • ALK • BCL2 • BCL6 • IRF4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • maplirpacept (TTI-622) • ontorpacept (PF-07901800)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 04/19/2023","start_date":" 04/19/2023","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-02-24"},{"id":"4405fdfb-3952-4954-a472-701ca7d88a54","acronym":"","url":"https://clinicaltrials.gov/study/NCT05821777","created_at":"2023-04-20T14:03:54.395Z","updated_at":"2025-02-25T13:49:46.186Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants with Advanced Solid Tumors","source_id_and_acronym":"NCT05821777","lead_sponsor":"Centessa Pharmaceuticals (UK) Limited","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e itanistomig (LB101)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/28/2023","start_date":" 03/28/2023","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 01/05/2027","study_completion_date":" 01/05/2027","last_update_posted":"2025-02-20"},{"id":"96f0f596-bee1-42fc-9dcc-41fcf8f78f40","acronym":"SL03-OHD-105","url":"https://clinicaltrials.gov/study/NCT05483933","created_at":"2022-08-02T12:55:49.417Z","updated_at":"2025-02-25T15:27:30.695Z","phase":"Phase 1","brief_title":"Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers","source_id_and_acronym":"NCT05483933 - SL03-OHD-105","lead_sponsor":"Shattuck Labs, Inc.","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 expression","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154"],"overall_status":"Completed","enrollment":" Enrollment 86","initiation":"Initiation: 08/18/2022","start_date":" 08/18/2022","primary_txt":" Primary completion: 02/07/2025","primary_completion_date":" 02/07/2025","study_txt":" Completion: 02/07/2025","study_completion_date":" 02/07/2025","last_update_posted":"2025-02-11"},{"id":"f1031737-80a9-4c8b-a2a6-14dc6ec95216","acronym":"SL03-OHD-104","url":"https://clinicaltrials.gov/study/NCT05275439","created_at":"2022-03-11T15:53:40.765Z","updated_at":"2025-02-25T15:44:45.150Z","phase":"Phase 1","brief_title":"Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects with MDS or AML","source_id_and_acronym":"NCT05275439 - SL03-OHD-104","lead_sponsor":"Shattuck Labs, Inc.","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • SL-172154"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 03/17/2022","start_date":" 03/17/2022","primary_txt":" Primary completion: 02/06/2025","primary_completion_date":" 02/06/2025","study_txt":" Completion: 02/06/2025","study_completion_date":" 02/06/2025","last_update_posted":"2025-02-11"},{"id":"84b9efcf-36bd-4449-8f61-5a867dd8b5f1","acronym":"NCI-2020-04163","url":"https://clinicaltrials.gov/study/NCT04435691","created_at":"2021-01-18T21:21:23.231Z","updated_at":"2025-02-25T16:37:56.003Z","phase":"Phase 1/2","brief_title":"Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia","source_id_and_acronym":"NCT04435691 - NCI-2020-04163","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • TP53 deletion","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • magrolimab (ONO-7913)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 07/28/2020","start_date":" 07/28/2020","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2025-02-06"},{"id":"963274c2-ef1a-43d9-bccd-99053c776187","acronym":"","url":"https://clinicaltrials.gov/study/NCT04599634","created_at":"2023-06-02T17:05:43.963Z","updated_at":"2025-02-25T16:53:20.802Z","phase":"Phase 1","brief_title":"Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies","source_id_and_acronym":"NCT04599634","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • BCL2","pipe":" | ","alterations":" TP53 mutation • CD20 positive","tags":["TP53 • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • magrolimab (ONO-7913) • methylprednisolone sodium succinate"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 12/16/2021","start_date":" 12/16/2021","primary_txt":" Primary completion: 03/29/2024","primary_completion_date":" 03/29/2024","study_txt":" Completion: 06/20/2024","study_completion_date":" 06/20/2024","last_update_posted":"2025-02-04"},{"id":"6bcd23c9-26d4-4ce6-8abc-592de885dbb3","acronym":"TWINPEAK","url":"https://clinicaltrials.gov/study/NCT05482893","created_at":"2022-08-01T14:54:48.052Z","updated_at":"2025-02-25T16:18:00.073Z","phase":"Phase 1/2","brief_title":"Spevatamig (PT886) for Treatment of Patients with Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study)","source_id_and_acronym":"NCT05482893 - TWINPEAK","lead_sponsor":"Phanes Therapeutics","biomarkers":" CLDN18","pipe":" | ","alterations":" HER-2 overexpression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • gemcitabine • 5-fluorouracil • capecitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • spevatamig (PT886)"],"overall_status":"Recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2025-01-31"},{"id":"cd1de8a7-094e-49cc-8165-4980d260787c","acronym":"SKYBRIDGE","url":"https://clinicaltrials.gov/study/NCT05652686","created_at":"2022-12-15T14:58:20.111Z","updated_at":"2025-02-25T16:27:12.251Z","phase":"Phase 1/2","brief_title":"A Study of Peluntamig (PT217) in Patients with Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)","source_id_and_acronym":"NCT05652686 - SKYBRIDGE","lead_sponsor":"Phanes Therapeutics","biomarkers":" EGFR • DLL3","pipe":" | ","alterations":" DLL3 expression","tags":["EGFR • DLL3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DLL3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin • paclitaxel • etoposide IV • peluntamig (PT217)"],"overall_status":"Recruiting","enrollment":" Enrollment 203","initiation":"Initiation: 09/05/2023","start_date":" 09/05/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2025-01-31"},{"id":"b8e5058b-32bb-4610-b262-21974b89110e","acronym":"SL03-OHD-101","url":"https://clinicaltrials.gov/study/NCT04406623","created_at":"2021-01-18T21:14:44.896Z","updated_at":"2025-02-25T17:30:15.356Z","phase":"Phase 1","brief_title":"Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer","source_id_and_acronym":"NCT04406623 - SL03-OHD-101","lead_sponsor":"Shattuck Labs, Inc.","biomarkers":" HRD","pipe":" | ","alterations":" HRD","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SL-172154"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 06/29/2020","start_date":" 06/29/2020","primary_txt":" Primary completion: 02/02/2023","primary_completion_date":" 02/02/2023","study_txt":" Completion: 02/02/2023","study_completion_date":" 02/02/2023","last_update_posted":"2025-01-30"},{"id":"688f7919-86e0-4ff0-8b2a-5d36de39804f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06487624","created_at":"2025-02-26T10:01:41.524Z","updated_at":"2025-02-26T10:01:41.524Z","phase":"Phase 1","brief_title":"An Engineered Sirpα Fused to Anti-Pd-L1 and Tgf-β Fusion Protein (HCB301) in Subjects with Selected Advanced Tumors","source_id_and_acronym":"NCT06487624","lead_sponsor":"FBD Biologics Limited","biomarkers":" TGFB1","pipe":"","alterations":" ","tags":["TGFB1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 01/30/2025","start_date":" 01/30/2025","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2024-12-11"},{"id":"5d8e201c-02bb-4867-adae-873e70735a40","acronym":"KEYNOTE-B87","url":"https://clinicaltrials.gov/study/NCT04675294","created_at":"2021-01-19T20:45:39.969Z","updated_at":"2025-02-25T16:10:57.319Z","phase":"Phase 2","brief_title":"Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)","source_id_and_acronym":"NCT04675294 - KEYNOTE-B87","lead_sponsor":"ALX Oncology Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • evorpacept (ALX148)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 189","initiation":"Initiation: 04/02/2021","start_date":" 04/02/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-07-22"},{"id":"19b483e0-e06b-49a5-9c96-b44876659d3f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05957536","created_at":"2023-07-24T15:08:43.228Z","updated_at":"2024-07-02T16:35:01.282Z","phase":"Phase 1","brief_title":"A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors","source_id_and_acronym":"NCT05957536","lead_sponsor":"D3 Bio (Wuxi) Co., Ltd","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e D3L-001"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 09/19/2023","start_date":" 09/19/2023","primary_txt":" Primary completion: 03/11/2026","primary_completion_date":" 03/11/2026","study_txt":" Completion: 03/11/2026","study_completion_date":" 03/11/2026","last_update_posted":"2024-05-23"},{"id":"1a85dab3-0f07-4f86-8f14-7eca6a3d7503","acronym":"ELEVATE HNSCC","url":"https://clinicaltrials.gov/study/NCT04854499","created_at":"2021-04-22T20:53:31.234Z","updated_at":"2024-07-02T16:35:02.553Z","phase":"Phase 2","brief_title":"Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT04854499 - ELEVATE HNSCC","lead_sponsor":"Gilead Sciences","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • docetaxel • 5-fluorouracil • Yutuo (zimberelimab) • magrolimab (ONO-7913)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 09/07/2021","start_date":" 09/07/2021","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-05-20"},{"id":"da2b0979-fceb-4b41-a878-bc533fb0df47","acronym":"","url":"https://clinicaltrials.gov/study/NCT05807126","created_at":"2023-04-11T14:03:25.975Z","updated_at":"2024-07-02T16:35:06.439Z","phase":"Phase 1","brief_title":"Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations","source_id_and_acronym":"NCT05807126","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNG • CD47 • BRCA • RAD51C • RAD51D • TGFB1 • IRF3","pipe":" | ","alterations":" HR positive • BRCA mutation • CD47 expression","tags":["IFNG • CD47 • BRCA • RAD51C • RAD51D • TGFB1 • IRF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • BRCA mutation • CD47 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • magrolimab (ONO-7913)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/05/2024","start_date":" 03/05/2024","primary_txt":" Primary completion: 12/06/2026","primary_completion_date":" 12/06/2026","study_txt":" Completion: 12/06/2026","study_completion_date":" 12/06/2026","last_update_posted":"2024-05-02"},{"id":"df1fa759-f871-48f7-b168-7af2f5b18c2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06046482","created_at":"2023-09-21T15:11:06.409Z","updated_at":"2024-07-02T16:35:09.810Z","phase":"Phase 2","brief_title":"Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT06046482","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • SIRPA","pipe":"","alterations":" ","tags":["PD-L1 • SIRPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • docetaxel • magrolimab (ONO-7913)"],"overall_status":"Suspended","enrollment":" Enrollment 57","initiation":"Initiation: 11/28/2023","start_date":" 11/28/2023","primary_txt":" Primary completion: 11/30/2027","primary_completion_date":" 11/30/2027","study_txt":" Completion: 11/30/2029","study_completion_date":" 11/30/2029","last_update_posted":"2024-04-12"},{"id":"2751da8c-36e6-4d17-a3c5-a7b73bf6d7a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04881045","created_at":"2021-05-11T11:52:56.882Z","updated_at":"2024-07-02T16:35:11.665Z","phase":"Phase 1","brief_title":"Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.","source_id_and_acronym":"NCT04881045","lead_sponsor":"Pfizer","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PF-07257876"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 08/18/2021","start_date":" 08/18/2021","primary_txt":" Primary completion: 10/24/2023","primary_completion_date":" 10/24/2023","study_txt":" Completion: 10/24/2023","study_completion_date":" 10/24/2023","last_update_posted":"2024-04-03"},{"id":"6599101d-aea2-4fda-beb6-038d37252237","acronym":"","url":"https://clinicaltrials.gov/study/NCT04440735","created_at":"2023-04-26T18:04:49.712Z","updated_at":"2024-07-02T16:35:11.822Z","phase":"Phase 1/2","brief_title":"A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04440735","lead_sponsor":"Kahr Medical","biomarkers":" EGFR • KRAS • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • KRAS wild-type • RET mutation • RAS wild-type","tags":["EGFR • KRAS • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • KRAS wild-type • RET mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • DSP-107"],"overall_status":"Recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 10/07/2020","start_date":" 10/07/2020","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-02"},{"id":"07e46b79-8fde-4376-b4a4-3d01c1ae210f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03558139","created_at":"2021-01-18T17:30:51.613Z","updated_at":"2025-02-25T16:07:59.888Z","phase":"Phase 1","brief_title":"Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy","source_id_and_acronym":"NCT03558139","lead_sponsor":"Gilead Sciences","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • magrolimab (ONO-7913)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 05/23/2018","start_date":" 05/23/2018","primary_txt":" Primary completion: 12/03/2020","primary_completion_date":" 12/03/2020","study_txt":" Completion: 12/03/2020","study_completion_date":" 12/03/2020","last_update_posted":"2024-04-01"},{"id":"12fc2fab-0693-4b13-abf9-14c2d2d11df7","acronym":"ELEVATELung\u0026UC","url":"https://clinicaltrials.gov/study/NCT04827576","created_at":"2021-04-01T15:52:23.578Z","updated_at":"2024-07-02T16:35:13.353Z","phase":"Phase 2","brief_title":"Study of Magrolimab in Patients With Solid Tumors","source_id_and_acronym":"NCT04827576 - ELEVATELung\u0026UC","lead_sponsor":"Gilead Sciences","biomarkers":" EGFR • ALK • ROS1 • NTRK","pipe":" | ","alterations":" MET exon 14 mutation","tags":["EGFR • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • magrolimab (ONO-7913)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-03-21"},{"id":"71d0abaf-a3de-40e4-9de3-0a76efd7b3a2","acronym":"ELEVATE TNBC","url":"https://clinicaltrials.gov/study/NCT04958785","created_at":"2022-04-08T23:52:35.380Z","updated_at":"2024-07-02T16:35:14.392Z","phase":"Phase 2","brief_title":"Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT04958785 - ELEVATE TNBC","lead_sponsor":"Gilead Sciences","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • PD-L1 negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • Trodelvy (sacituzumab govitecan-hziy) • magrolimab (ONO-7913)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 12/14/2021","start_date":" 12/14/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-03-15"},{"id":"f98339f3-8da6-4706-ab29-7a338e6db7fa","acronym":"TTI-622-01","url":"https://clinicaltrials.gov/study/NCT03530683","created_at":"2021-07-15T16:53:02.099Z","updated_at":"2024-07-02T16:35:25.423Z","phase":"Phase 1","brief_title":"A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma","source_id_and_acronym":"NCT03530683 - TTI-622-01","lead_sponsor":"Pfizer","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • TP53 wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • azacitidine • carfilzomib • Sarclisa (isatuximab-irfc) • dexamethasone injection • maplirpacept (TTI-622)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 177","initiation":"Initiation: 06/07/2018","start_date":" 06/07/2018","primary_txt":" Primary completion: 09/11/2024","primary_completion_date":" 09/11/2024","study_txt":" Completion: 09/11/2024","study_completion_date":" 09/11/2024","last_update_posted":"2023-12-22"},{"id":"5064553d-e4ed-498f-bc5e-f6c9536a84d7","acronym":"CSG-1906-101","url":"https://clinicaltrials.gov/study/NCT05857332","created_at":"2023-05-12T17:05:01.178Z","updated_at":"2024-07-02T16:35:28.556Z","phase":"Phase 1","brief_title":"SG1906 for CLDN18.2-Positive Solid Tumors","source_id_and_acronym":"NCT05857332 - CSG-1906-101","lead_sponsor":"Hangzhou Sumgen Biotech Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SG1906"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 08/30/2025","study_completion_date":" 08/30/2025","last_update_posted":"2023-11-21"},{"id":"8f2eeb60-09f0-4084-b1ee-ab86329273ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT04485052","created_at":"2022-04-24T09:02:43.518Z","updated_at":"2024-07-02T16:35:32.242Z","phase":"Phase 1/2","brief_title":"Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT04485052","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • decitabine • letaplimab (IBI188)"],"overall_status":"Suspended","enrollment":" Enrollment 222","initiation":"Initiation: 09/25/2020","start_date":" 09/25/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-10-23"},{"id":"62fd86f9-af84-448e-80e9-4156070ebb79","acronym":"","url":"https://clinicaltrials.gov/study/NCT04853329","created_at":"2021-04-21T11:53:38.802Z","updated_at":"2024-07-02T16:35:32.261Z","phase":"Phase 1/2","brief_title":"Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma","source_id_and_acronym":"NCT04853329","lead_sponsor":"Conjupro Biotherapeutics, Inc.","biomarkers":" BCL2 • CD20","pipe":" | ","alterations":" CD20 positive","tags":["BCL2 • CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JMT601"],"overall_status":"Suspended","enrollment":" Enrollment 7","initiation":"Initiation: 12/13/2021","start_date":" 12/13/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-10-20"}]